Roberto S Accolla

List of Publications by Year
in descending order

145 papers	3,934 citations	136950 32 h-index	138484 58 g-index
150 all docs	150 docs citations	150 times ranked	3611 citing authors

#	Article	IF	Citations
1	Use of radiolabelled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy. Trends in Immunology, 1981, 2, 239-249.	7.5	344
2	Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28â^' T cells and inhibit both T-Cell proliferation and CTL function. Human Immunology, 2004, 65, 142-156.	2.4	151
3	Subsets of human Ia-like molecules defined by monoclonal antibodies. Molecular Immunology, 1981, 18, 403-411.	2.2	149
4	Different staphylococcal enterotoxins bind preferentially to distinct major histocompatibility complex class ii isotypes. European Journal of Immunology, 1989, 19, 2171-2174.	2.9	124
5	Reducing the global burden of HTLV-1 infection: An agenda for research and action. Antiviral Research, 2017, 137, 41-48.	4.1	116
6	Distinct HLA-DR epitopes and distinct families of HLA-DR molecules defined by 15 monoclonal antibodies (mAb) either anti-DR or allo-anti-Iak crossreacting with human DR molecule. I. Cross-inhibition studies of mAb cell surface fixation and differential binding of mAb to detergent-solubilized HLA molecules immobilized to a solid phase by a first mAb. European Journal of Immunology, 1983, 13, 106-111.	2.9	111
7	The genes for lumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta) are tandemly arranged on chromosome 17 of the mouse. Nucleic Acids Research, 1986, 14, 7713-7725.	14.5	108
8	Isolation of distinct cDNA clones encoding HLA-DR beta chains by use of an expression assay.. Proceedings of the National Academy of Sciences of the United States of America, 1982, 79, 7465-7469.	7.1	105
9	CELL lineage-specific and developmental stage-specific controls of MHC class-II-antigen expression. International Journal of Cancer, 1991, 47, 20-25.	5.1	100
10	Isolation of cDNA clones encoding HLA-DR alpha chains.. Proceedings of the National Academy of Sciences of the United States of America, 1982, 79, 6979-6983.	7.1	97
11	Dendritic Cell Editing by Activated Natural Killer Cells Results in a More Protective Cancer-Specific Immune Response. PLoS ONE, 2012, 7, e39170.	2.5	95
12	Targeted Delivery of Tumor Necrosis Factor-Î± to Tumor Vessels Induces a Therapeutic T Cellâ€“Mediated Immune Response that Protects the Host Against Syngeneic Tumors of Different Histologic Origin. Clinical Cancer Research, 2006, 12, 2575-2582.	7.0	85
13	CIITA-Induced MHC Class II Expression in Mammary Adenocarcinoma Leads to a Th1 Polarization of the Tumor Microenvironment, Tumor Rejection, and Specific Antitumor Memory. Clinical Cancer Research, 2006, 12, 3435-3443.	7.0	79
14	Down syndrome, autoimmunity and T regulatory cells. Clinical and Experimental Immunology, 2012, 169, 238-243.	2.6	78
15	Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells. European Journal of Immunology, 2003, 33, 1183-1192.	2.9	73
16	Pancreatic cancer in europe: Ki-ras gene mutation pattern shows geographical differences. International Journal of Cancer, 1994, 57, 167-171.	5.1	72
17	Tat Protein Is an HIV-1-Encoded Î²-Chemokine Homolog That Promotes Migration and Up-Regulates CCR3 Expression on Human FcÎµRI+ Cells. Journal of Immunology, 2000, 165, 7171-7179.	0.8	67
18	CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine. Frontiers in Immunology, 2019, 10, 1806.	4.8	63

#	Article	IF	Citations
19	Ia-negative B-cell variants reveal a coordinate regulation in the transcription of the HLA Class II gene family. Immunogenetics, 1984, 19, 349-353.	2.4	57
20	Active suppression of major histocompatibility complex class II gene expression during differentiation from B cells to plasma cells.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 2229-2233.	7.1	57
21	Binding of one monoclonal antibody to human Ia molecules can be enhanced by a second monoclonal antibody. European Journal of Immunology, 1981, 11, 721-726.	2.9	56
22	APC gene mutations and allelic losses in sporadic ampullary tumours: Evidence of genetic difference from tumours associated with familial adenomatous polyposis. , 1996, 68, 305-312.		55
23	ras-family gene mutations in neoplasia of the ampulla of vater. International Journal of Cancer, 1994, 59, 39-42.	5.1	53
24	Therapyâ€induced antitumor vaccination in neuroblastomas by the combined targeting of ILâ€2 and TNFÎ±. International Journal of Cancer, 2010, 127, 101-110.	5.1	50
25	Somatic cell hybrids producing antibodies specific to human fibronectin. International Journal of Cancer, 1980, 25, 325-329.	5.1	46
26	NK cells provide helper signal for CD8+ T cells by inducing the expression of membrane-bound IL-15 on DCs. International Immunology, 2009, 21, 599-606.	4.0	46
27	Demonstration at the single-cell level of the existence of distinct clusters of epitopes in two predefined human Ia molecular subsets. European Journal of Immunology, 1982, 12, 166-169.	2.9	44
28	231 The MHC Class II Transactivator, CIITA, is a Viral Restriction Factor for Human Oncogenic Retroviruses. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 100.	2.1	43
29	Constitutive expression of CD69 in interspecies T-cell hybrids and locus assignment to human chromosome 12. Immunogenetics, 1992, 36, 117-120.	2.4	42
30	Therapyâ€induced antitumor vaccination by targeting tumor necrosis factorâ€Î± to tumor vessels in combination with melphalan. European Journal of Immunology, 2007, 37, 3381-3392.	2.9	41
31	The MHC class II transactivator: prey and hunter in infectious diseases. Trends in Immunology, 2001, 22, 560-563.	6.8	40
32	Boosting the MHC Class II-Restricted Tumor Antigen Presentation to CD4+ T Helper Cells: A Critical Issue for Triggering Protective Immunity and Re-Orienting the Tumor Microenvironment Toward an Anti-Tumor State. Frontiers in Oncology, 2014, 4, 32.	2.8	40
33	Cytoplasmic Localization of HTLV-1 HBZ Protein: A Biomarker of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP). PLoS Neglected Tropical Diseases, 2017, 11, e0005285.	3.0	35
34	Localization, quantification and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL. Retrovirology, 2015, 12, 59.	2.0	34
35	Human adipose-derived stem cells promote vascularization of collagen-based scaffolds transplanted into nude mice. Regenerative Medicine, 2016, 11, 261-271.	1.7	34
36	HTLV-1 HBZ Viral Protein: A Key Player in HTLV-1 Mediated Diseases. Frontiers in Microbiology, 2017, 8, 2615.	3.5	34

#	Article	IF	Citations
37	Monoclonal antibodies against carcinoembryonic antigen (CEA) used in a solid-phase enzyme immunoassay. First clinical results. Journal of Immunological Methods, 1982, 49, 129-139.	1.4	32
38	The HLAâ€„classâ€„II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication. European Journal of Immunology, 2002, 32, 2783-2791.	2.9	32
39	Major Histocompatibility Complex Class II Transactivator CIITA Is a Viral Restriction Factor That Targets Human T-Cell Lymphotropic Virus Type 1 Tax-1 Function and Inhibits Viral Replication. Journal of Virology, 2011, 85, 10719-10729.	3.4	31
40	Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma. Clinical Cancer Research, 2022, 28, 2555-2566.	7.0	31
41	Active suppression of the class II transactivator-encodingAIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells. European Journal of Immunology, 1996, 26, 2456-2460.	2.9	30
42	Proliferative activity of extracellular HIV-1 Tat protein in human epithelial cells: expression profile of pathogenetically relevant genes. BMC Microbiology, 2005, 5, 20.	3.3	30
43	The Major Histocompatibility Complex Class II Transactivator CIITA Inhibits the Persistent Activation of NF-ÎºB by the Human T Cell Lymphotropic Virus Type 1 Tax-1 Oncoprotein. Journal of Virology, 2016, 90, 3708-3721.	3.4	30
44	Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR. European Journal of Immunology, 2000, 30, 1120-1126.	2.9	29
45	CIITA-driven MHC class II expressing tumor cells can efficiently prime naive CD4⁺TH cellsin vivoand vaccinate the host against parental MHC-II-negative tumor cells. OncoImmunology, 2017, 6, e1261777.	4.6	29
46	Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions. International Immunology, 2009, 21, 655-665.	4.0	28
47	CIITAâ€driven MHCâ€II positive tumor cells: Preventive vaccines and superior generators of antitumor CD4⁺ T lymphocytes for immunotherapy. International Journal of Cancer, 2010, 127, 1614-1624.	5.1	28
48	Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines. Journal of Translational Medicine, 2012, 10, 154.	4.4	28
49	MHC: orchestrating the immune response. Trends in Immunology, 1995, 16, 8-11.	7.5	26
50	Different levels of control prevent interferon-Î³-inducible HLA-class II expression in human neuroblastoma cells. Oncogene, 2003, 22, 7848-7857.	5.9	26
51	HIV-1 Tat mutants in the cysteine-rich region downregulate HLA class II expression in T lymphocytic and macrophage cell lines. European Journal of Immunology, 2000, 30, 19-28.	2.9	25
52	Structural analysis of the CD69 early activation antigen by two monoclonal antibodies directed to different epitopes. Molecular Immunology, 1991, 28, 159-168.	2.2	24
53	The MHC class II transcriptional activator (CIITA) inhibits HTLV-2 viral replication by blocking the function of the viral transactivator Tax-2. Blood, 2004, 103, 995-1001.	1.4	24
54	CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches. OncoImmunology, 2019, 8, 1548243.	4.6	24

#	Article	IF	Citations
55	Reversible Human Immunodeficiency Virus Type-1 Latency in Primary Human Monocyte-Derived Macrophages Induced by Sustained M1 Polarization. Scientific Reports, 2018, 8, 14249.	3.3	23
56	Distinct regulation of HLA class II and class I cell surface expression in the THP-1 macrophage cell line after bacterial phagocytosis. European Journal of Immunology, 1999, 29, 499-511.	2.9	22
57	HTLV-1 HBZ Protein Resides Exclusively in the Cytoplasm of Infected Cells in Asymptomatic Carriers and HAM/TSP Patients. Frontiers in Microbiology, 2019, 10, 819.	3.5	22
58	CIITA-Transduced Glioblastoma Cells Uncover a Rich Repertoire of Clinically Relevant Tumor-Associated HLA-II Antigens. Molecular and Cellular Proteomics, 2021, 20, 100032.	3.8	22
59	Antibody-mediated activation of a deletion-mutant Î²-galactosidase defective in the Î± region. FEBS Letters, 1976, 67, 299-302.	2.8	21
60	Sandwich enzyme immunoassay using three monoclonal antibodies against different epitopes of carcinoembryonic antigen (CEA). Immunology Letters, 1982, 5, 85-91.	2.5	21
61	The importance of cross-reactions between species: Mouse allo-anti-Ia monoclonal antibodies as a powerful tool to define human Ia subsets. Human Immunology, 1983, 8, 75-82.	2.4	21
62	Inhibition of human T cell leukemia virus type 2 replication by the suppressive action of class II transactivator and nuclear factor Y. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 12861-12866.	7.1	21
63	The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells. Journal of Translational Medicine, 2016, 14, 94.	4.4	20
64	Block of Stat-1 activation in macrophages phagocytosing bacteria causes reduced transcription of CIITA and consequent impaired antigen presentation. European Journal of Immunology, 2002, 32, 1309.	2.9	19
65	The complex interplay of the DQB1 and DQA1 loci in the generation of the susceptible and protective phenotype for insulin-dependent diabetes mellitus. Molecular Immunology, 1994, 31, 429-437.	2.2	16
66	The MHC-II transactivator CIITA, a restriction factor against oncogenic HTLV-1 and HTLV-2 retroviruses: similarities and differences in the inhibition of Tax-1 and Tax-2 viral transactivators. Frontiers in Microbiology, 2013, 4, 234.	3.5	16
67	Tumor Immunology meetsâ€¦Immunology: Modified cancer cells as professional APC for priming naÃ¯ve tumor-specific CD4+ T cells. OncoImmunology, 2017, 6, e1356149.	4.6	16
68	Tripartite Motif-Containing Protein 22 Interacts with Class II Transactivator and Orchestrates Its Recruitment in Nuclear Bodies Containing TRIM19/PML and Cyclin T1. Frontiers in Immunology, 2017, 8, 564.	4.8	16
69	Epigenetic silencing of HTLV-1 expression by the HBZ RNA through interference with the basal transcription machinery. Blood Advances, 2020, 4, 5574-5579.	5.2	16
70	Class II Transactivator-Induced MHC Class II Expression in Pancreatic Cancer Cells Leads to Tumor Rejection and a Specific Antitumor Memory Response. Pancreas, 2014, 43, 1066-1072.	1.1	14
71	Restriction factors in human retrovirus infections and the unprecedented case of CIITA as link of intrinsic and adaptive immunity against HTLV-1. Retrovirology, 2019, 16, 34.	2.0	14
72	The MHC class?II transactivator (CIITA) mRNA stability is critical for the HLA class?II gene expression in myelomonocytic cells. European Journal of Immunology, 2005, 35, 603-611.	2.9	13

#	Article	IF	Citations
73	Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN-Â in promyelocytic cells. International Immunology, 2008, 20, 1457-1466.	4.0	13
74	Molecular and cellular correlates of the CIITA-mediated inhibition of HTLV-2 Tax-2 transactivator function resulting in loss of viral replication. Journal of Translational Medicine, 2011, 9, 106.	4.4	13
75	In vivo modification of major histocompatibility complex class II DRA promoter occupancy mediated by the AIR-1 trans-activator. European Journal of Immunology, 1994, 24, 2415-2420.	2.9	12
76	Double-stranded deoxyribonucleic acid binds to HLA class II molecules and inhibits HLA class II-mediated antigen presentation. European Journal of Immunology, 1998, 28, 3968-3979.	2.9	12
77	Identification of Immunodominant Epitopes in Inactivated Tat-Vaccinated Healthy and HIV-1â€“Infected Volunteers. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 47-55.	2.1	12
78	Experimental therapeutic approaches to adenocarcinoma: The potential of tumor cells engineered to express MHC class II molecules combined with naked DNA interleukin-12 gene transfer. Surgical Oncology, 2007, 16, 33-36.	1.6	12
79	Dual cytoplasmic and nuclear localization of HTLV-1-encoded HBZ protein is a unique feature of adult T cell leukemia. Haematologica, 2021, 106, 2076-2085.	3.5	12
80	HLA-DQB1 typing of north east Italian IDDM patients using amplified DNA, oligonucleotide probes and a rapid DNA-enzyme immunoassay (DEIA). Molecular Immunology, 1993, 30, 69-76.	2.2	11
81	Human T-Cell Leukemia Virus Type II Directly Acts on CD34+ Hematopoietic Precursors by Increasing Their Survival Potential. Envelope-Associated HLA Class II Molecules Reverse This Effect. Blood, 1998, 91, 2296-2304.	1.4	11
82	Adequate Antigen Availability: A Key Issue for Novel Approaches to Tumor Vaccination and Tumor Immunotherapy. Journal of NeuroImmune Pharmacology, 2013, 8, 28-36.	4.1	10
83	Interferon-inducible TRIM22 contributes to maintenance of HIV-1 proviral latency in T cell lines. Virus Research, 2019, 269, 197631.	2.2	10
84	Host Defense Mechanisms against Pathogens. Surgical Infections, 2006, 7, s-5-s-7.	1.4	9
85	Unveiling the Hidden Treasury: CIITA-Driven MHC Class II Expression in Tumor Cells to Dig up the Relevant Repertoire of Tumor Antigens for Optimal Stimulation of Tumor Specific CD4+ T Helper Cells. Cancers, 2020, 12, 3181.	3.7	9
86	The dual function of the MHC class II transactivator CIITA against HTLV retroviruses. Frontiers in Bioscience, 2009, 14, 4149-56.	2.1	9
87	Tripartite Motif 22 and Class II Transactivator Restriction Factors: Unveiling Their Concerted Action against Retroviruses. Frontiers in Immunology, 2017, 8, 1362.	4.8	8
88	A family of trans-acting factors with distinct regulatory functions control expression of MHC class II genes. Immunologic Research, 1990, 9, 20-33.	2.9	7
89	Analysis of the antigen specific T cell repertoires in HIV infection. Immunology Letters, 2001, 79, 85-91.	2.5	7
90	HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients.. Journal of Clinical Oncology, 2018, 36, TPS3135-TPS3135.	1.6	7

#	Article	IF	Citations
91	Editorial: Novel Strategies for Anti-Tumor Vaccines. Frontiers in Immunology, 2019, 10, 3117.	4.8	7
92	Physiologic target of the Air-1 trans-activator revealed by stable transfection assay. Immunogenetics, 1994, 39, 8-14.	2.4	6
93	Typing of a Polymorphic Human Gene Conferring Susceptibility to Insulin-Dependent Diabetes Mellitus by Picosecond-Resolved FRET on Non-Purified/Non-Amplified Genomic DNA. DNA Research, 2012, 19, 347-355.	3.4	6
94	Molecular genotyping of the HLA-DQ ? gene region. Immunogenetics, 1988, 27, 12-18.	2.4	5
95	Human Naive CD4 T-Cell Clones Specific for HIV Envelope Persist for Years In Vivo in the Absence of Antigenic Challenge. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 132-139.	2.1	5
96	Abstract LB-094: Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma. Cancer Research, 2020, 80, LB-094-LB-094.	0.9	5
97	MHC class II gene regulation: some historical considerations on a still ontogenetic and phylogenetic puzzle. Microbes and Infection, 1999, 1, 871-877.	1.9	4
98	MHC immunoevasins: protecting the pathogen reservoir in infection. Tissue Antigens, 2005, 66, 2-8.	1.0	4
99	Divergent evolution in the mechanisms controlling major histocompatibility complex class II gene transcription in mouse and human. European Journal of Immunology, 1996, 26, 259-262.	2.9	3
100	Neonatal Fc receptor is involved in the protection of fibrinogen after its intake in peripheral blood mononuclear cells. Journal of Translational Medicine, 2018, 16, 64.	4.4	3
101	Investigating Human T Cell Lymphotropic Retrovirus (HTLV) Tax Function with Molecular and Immunophenotypic Techniques. Methods in Molecular Biology, 2014, 1087, 299-313.	0.9	3
102	Unsung Hero Robert C. Gallo. Science, 2009, 323, 206-207.	12.6	2
103	New Strategies of Mammary Cancer Vaccination. Breast Journal, 2010, 16, S42-S44.	1.0	2
104	Distinct regulation of HLA class II and class I cell surface expression in the THP-1 macrophage cell line after bacterial phagocytosis. European Journal of Immunology, 1999, 29, 499-511.	2.9	2
105	Superinfection by Epstein-Barr virus of a subset of Raji cells is independent of HLA class-II antigens. International Journal of Cancer, 1990, 45, 989-989.	5.1	1
106	Evidence for a trans-acting activator function regulating the expression of the human CD5 antigen. Immunogenetics, 1994, 40, 217-221.	2.4	1
107	Time-Resolved FÃ¶rster Resonance Energy Transfer Analysis of Single-Nucleotide Polymorphisms: Towards Molecular Typing of Genes on Non-Purified and Non-PCR-Amplified DNA. Journal of Molecular Biology Research, 2013, 3, .	0.1	1
108	The MHC Class II transactivator CIITA inhibits the persistent activation of NF-kB by Tax-1. Retrovirology, 2015, 12, .	2.0	1

#	Article	IF	Citations
109	P-D2 TRIM22 binds to CIITA and sequesters it into nuclear bodies containing TRIM19/PML and Cyclin T1: Implications for HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 59-59.	2.1	1
110	D-105 Reversible HIV-1 Latency Induced in Primary Human Monocyte-Derived Macrophages by Repeated M1 Polarization. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 40-40.	2.1	1
111	Abstract 2354: Cancer vaccine development for hepatocellular carcinoma - HEPAVAC. Cancer Research, 2016, 76, 2354-2354.	0.9	1
112	Fowlpoxvirus recombinants coding for the CIITA gene increase the expression of endogenous MHC-II and Fowlpox Gag/Pro and Env SIV transgenes. PLoS ONE, 2018, 13, e0190869.	2.5	1
113	Monoclonal Antibodies as a Tool to Detect Melanoma-Associated Antigens. , 1982, , 53-73.		1
114	Human T-Cell Leukemia Virus Type II Directly Acts on CD34+ Hematopoietic Precursors by Increasing Their Survival Potential. Envelope-Associated HLA Class II Molecules Reverse This Effect. Blood, 1998, 91, 2296-2304.	1.4	1
115	Biochemical aspects of human Ia molecules. Human Immunology, 1983, 8, 41-43.	2.4	0
116	The MHC Class II Transactivator (CIITA): A "Physiologic" Drug Against HIV-1 Replication. Retrovirology, 2005, 2, P2.	2.0	0
117	Title is missing!. Retrovirology, 2005, 2, S55.	2.0	0
118	7he MHC Class II Transactivator (CIITA): A Physiologic Inhibitor of HTLV-2 Retroviral Infection. Retrovirology, 2005, 2, P5.	2.0	0
119	A dual defensive role of CIITA against retroviral infections. Retrovirology, 2006, 3, S102.	2.0	0
120	153 Insight into the molecular mechanism of CIITA-mediated inhibition of HIV-1 and HTLV transactivators. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, .	2.1	0
121	202 The MHC Class II Transactivator CIITA, a Restriction Factor for Human Retroviruses and a Molecule Making the Bridge Between Adaptive and Intrinsic Immunity. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 86.	2.1	0
122	136 HTLV-2 Tax-2 Transactivator Increases the Expression and the Function of its Inhibitor CIITA, the Master Regulator of HLA-II Gene Transcription. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 55.	2.1	0
123	The MHC-II transactivator CIITA, a viral restriction factor inhibiting the replication of Human T-Cell Lymphotropic Virus Type 1. Retrovirology, 2011, 8, .	2.0	0
124	MHC class II transactivator CIITA inhibits Tax-2-mediated HTLV-2 LTR transactivation and viral replication by binding to, and affecting Tax-2 intracellular localization. Retrovirology, 2011, 8, A172.	2.0	0
125	E1â€ƒMolecular and Cellular Correlates of the CIITA-Mediated Inhibition of HTLV-2 Tax-2 Transactivator Function Resulting in Loss of Viral Replication. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 82.	2.1	0
126	E2â€ƒThe MHC-II Transactivator CIITA, a Viral Restriction Factor Targeting Human T-Cell Lymphotropic Virus Type 1 Tax-1 Function and Inhibiting Viral Replication. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 82.	2.1	0

#	Article	IF	Citations
127	Picosecond-resolved FRET on non-amplified DNA for identifying individuals genetically susceptible to type-1 diabetes. Proceedings of SPIE, 2012, , .	0.8	0
128	P105â€ƒThe MHC-II transactivator CIITA is a viral restriction factor against HIV-1 replication. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 73.	2.1	0
129	P104â€ƒSuitable Antigen Availability. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 72.	2.1	0
130	P101â€ƒThe MHC-II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kBactivation. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 71.	2.1	0
131	The MHC Class II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kB activation. Retrovirology, 2014, 11, P64.	2.0	0
132	Localization, quantization and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL. Retrovirology, 2015, 12, .	2.0	0
133	Localization, quantization and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL. Retrovirology, 2015, 12, .	2.0	0
134	B-104 Cancer vaccine: Tumor immunology meets...Immunology. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 36-36.	2.1	0
135	A-104â€ƒTracing the intracellular journey of HTLV-1 HBZ during infection: From asymptomatic carriers to HAM/TSP ending to ATL: A one-way ticket?. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 32-32.	2.1	0
136	HTLV-1 Infection and Adult T Cell Leukemia Mechanisms of Oncogenesis and Alteration of Immunity. , 2021, , .		0
137	The AIR-1 encoded class II transactivator (CIITA): the master coordinator of MHC class II gene expression and ..more. Advances in Experimental Medicine and Biology, 2001, 495, 83-91.	1.6	0
138	224 The MHC-II Transactivator, CIITA, Inhibits Tat-Mediated HIV-1 LTR Transactivation and Virus Replication in Human U937 Monocytic Cells. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 97.	2.1	0
139	Role of the HLA-DQ Genotype in IDDM Susceptibility. Medical Science Symposia Series, 1994, , 21-26.	0.0	0
140	Abstract B048: The MHC class II transactivator CIITA inhibits the persistent activation of NF-kB by Human T cell Lymphotropic Virus type-1 Tax-1 oncoprotein. , 2016, , .		0
141	Abstract B047: Adequate Antigen Availability (AAA) in antitumor immunity: Definition and consequences for novel strategies of tumor prevention and antitumor treatment. , 2016, , .		0
142	Abstract A115: Cancer vaccine development for hepatocellular carcinoma â€“ HEPAVAC. , 2016, , .		0
143	Abstract A014: CIITA dependent MHC class II IA expression in tumor cells triggers CD4 T cell protective and long lasting antitumor immunity. , 2016, , .		0
144	Abstract A043: Discovery to first-in-man studies of a multi-peptide-based hepatocellular carcinoma vaccine adjuvanted with CV8102 (RNAdjuvantÂ®): HEPAVAC. , 2016, , .		0

#	Article	IF	Citations
145	The Road to HTLV-1-Induced Leukemia by Following the Subcellular Localization of HTLV-1-Encoded HBZ Protein. Frontiers in Immunology, 0, 13, .	4.8	0